Trial Profile
Therapeutic reactivity of Ustekinumab in moderate to severe active stage Crohn's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 31 Jan 2022 Status changed from recruiting to completed.
- 11 Jul 2017 New trial record